Beta Blockers and Sex Drive: What the Trials Actually Show
Share
Do beta blockers lower sex drive? Far less than their reputation says. Pooled across 15 randomized trials covering more than 35,000 subjects, beta blocker therapy carried about 5 extra reports of sexual dysfunction per 1000 patients per year (95% CI 2 to 8), one additional report for every 199 people treated for a year (Ko et al., 2002). That is a real signal and a small one. The bigger finding is how much of the reported effect moves with what the patient was told about the drug beforehand, and the drop in desire people describe is real even when the pill turns out to be the wrong suspect.
Read this part first: do not stop or change your blood pressure medication on your own.
Nothing here is a reason to skip a dose, halve a tablet, or quit a prescription. Blood pressure medication is prescribed for good reasons and it works. Any decision to switch drugs or classes belongs to you and your prescriber. If your sex drive changed after you started one, book the conversation.
- Across 15 randomized trials and more than 35,000 subjects, beta blockers added roughly 5 reports of sexual dysfunction per 1000 patients per year, one per 199 treated per year (Ko et al., 2002).
- A network meta-analysis of 25 studies and 7,784 patients found no class separating from placebo. Its authors rated risk of bias as concerning or high in most included studies, so that null certifies nothing as safe (Farmakis et al., 2022).
- In 96 men on atenolol, reported erectile dysfunction ran 3.1% when they were blinded to the drug, 15.6% when told its name, and 31.2% when told the name and its side effects (P less than 0.01). Placebo reversed it as well as sildenafil did (Silvestri et al., 2003). One trial, all male.
- This evidence is overwhelmingly about men. Women were 345 of the 902 patients in the one long-term trial measuring both, where their rates stayed low and did not vary by drug class (Grimm et al., 1997).
Figures from Ko et al. 2002 (PMID 12117400) and Farmakis et al. 2022 (PMID 33945044).
What the pooled trials counted, and what they found
Ko and colleagues at Yale went looking for the evidence behind a clinical habit. Doctors were holding back beta blockers from cardiac patients who stood to benefit, out of worry about depression, exhaustion, and sexual side effects. The team searched MEDLINE from 1966 to 2001, requiring randomization, a placebo control, no crossover, at least 100 patients, and six months of follow-up. Of 475 articles, 42 cleared those bars and 15 reported on the three symptoms, covering more than 35,000 subjects.
Sexual dysfunction rose by 5 reports per 1000 patients per year, confidence interval 2 to 8, so the effect cleared significance and stayed small. Fatigue rose by 18 per 1000 per year (95% CI 5 to 30), one extra report per 57 treated per year. Depressive symptoms moved 6 per 1000 per year on an interval running from minus 7 to 19, which crosses zero and means the trials could not tell it apart from chance. Lipid solubility, long blamed for the central nervous system effects, changed none of the three.
The authors put it plainly: the conventional wisdom that beta blocker therapy carries substantial risks of depressive symptoms, fatigue, and sexual dysfunction is unsupported by the clinical trial data (Ko et al., 2002). One extra report per 199 patient-years counts for something, and it sits nowhere near the story that circulates in forums and waiting rooms.
Is it the pill or is it me?
Silvestri and colleagues enrolled 96 men, mean age 52, all newly diagnosed with cardiovascular disease and none reporting sexual difficulty at baseline. Everyone got atenolol 50mg once daily. The only variable was information. Group A, 32 men, were blinded to the drug. Group B, 32 men, were told its name and nothing more. Group C, 32 men, were told the name and briefed on its effects on erectile function.
After three months, reported erectile dysfunction came in at 3.1% in group A, 15.6% in group B, and 31.2% in group C, at P less than 0.01. Same molecule, same dose, and a tenfold spread produced by what the men knew.
Same drug, same dose, three different briefings
Reported erectile dysfunction after three months on atenolol 50mg daily, by what each group was told. One trial, 96 men, 32 per group, all male.
Source: Silvestri A, Galetta P, Cerquetani E, et al., European Heart Journal 2003 (PMID 14585251). Single-centre trial in 96 men with newly diagnosed cardiovascular disease. Male-only, one erectile-function endpoint, never replicated at this design.
In the second phase, every man reporting a problem moved into a crossover comparison of sildenafil 50mg against placebo, and both reversed the difficulty in all but one patient, about equally well. A dummy tablet undid what the beta blocker was being blamed for.
The men in group C were describing something they genuinely experienced. Anxiety about a drug is a physical state with real consequences in the bedroom, and the authors said so: knowledge and prejudice about beta blocker side effects can produce anxiety, and the anxiety carries through. Anyone reading that trial as "it is all in your head" has read it wrong. The experience is real; the attribution is what the data questions. Hold the distinction, because the first version gets you dismissed and the second gives you a solvable problem.
One trial, 96 men, one drug at one dose at one site, never repeated. Nobody else has isolated the mechanism this cleanly.
When every drug class was compared head to head
If beta blockers are the villain of this story, the comparison should show them losing to the other classes. Farmakis and colleagues ran it. Their frequentist network meta-analysis put ACE inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, and thiazide diuretics against each other and against placebo, registered in advance on PROSPERO, covering 25 studies and 7,784 patients.
No significant differences turned up in any pairwise comparison between the major classes, and with placebo as the reference, no treatment strategy produced a significant effect either. Inside the beta blocker family, nebivolol beat non-vasodilating beta blockers (OR 2.92, 95% CI 1.3 to 6.5) while failing to beat placebo (OR 2.87, 95% CI 0.75 to 11.04). The authors concluded that all antihypertensive classes seem to exert neutral or insignificant effects (Farmakis et al., 2022).
Carry the caveat with the result, because the authors put it in their own abstract: risk of bias was concerning or high in the majority of included studies, and inconsistency was high too. A null drawn from a shaky base tells you the confident class-by-class rankings you see online have no trial support underneath them. Certifying any drug as harmless would take better studies.
Reputation against measurement, class by class
| Drug class | Its reputation | What the randomized data measured |
|---|---|---|
| Beta blockers (metoprolol, atenolol, acebutolol) | The classic libido killer, blamed first | 5 extra reports per 1000 patients per year across 15 trials, one per 199 treated. In TOMHS, acebutolol tracked placebo through 48 months. |
| ACE inhibitors (lisinopril, enalapril) | Called the gentle option | Enalapril in TOMHS was similar to placebo, and no separation from placebo in the 25-study network, on an evidence base rated concerning or high risk of bias. |
| Angiotensin receptor blockers (losartan, valsartan) | Marketed as actively protective | No significant effect against placebo, and no edge over any other class. |
| Calcium channel blockers (amlodipine) | Assumed neutral | Amlodipine in TOMHS was similar to placebo. The assumption survives, on thin data. |
| Thiazide diuretics (chlorthalidone) | Lumped in as an afterthought | The one significant randomized signal here: 17.1% of men on chlorthalidone through 24 months against 8.1% on placebo (P equal to .025), with the gap shrinking to non-significance by 48 months. |
Trial data from Ko et al. 2002 (PMID 12117400), Farmakis et al. 2022 (PMID 33945044), and Grimm et al. 1997, the TOMHS trial (PMID 9039073).
The surprise is in the bottom row. The class with the loud reputation produced a small effect, and the class nobody talks about produced the only significant one. Even that faded: by 48 months the rates had converged.
Lisinopril, metoprolol, and the names people actually search
Metoprolol is a beta blocker, so the Ko pooled analysis is the right frame, and it found small effects with no dependence on lipid solubility. The metoprolol-specific worry about the drug crossing into the brain and flattening mood has no support there. Metoprolol has never been tested alone against placebo on a sexual endpoint in a trial large enough to say anything drug-specific, so anyone quoting you a metoprolol number is quoting a forum.
Lisinopril is an ACE inhibitor. Its close relative enalapril represented the class in TOMHS, with erection problems tracking the placebo group across four years of double-blind follow-up, and ACE inhibitors showed no significant separation from placebo in the 25-study network. So the evidence does not link lisinopril to sexual side effects, and it is thin enough that it cannot rule out a small effect either. Check both against your own timeline, since a drug started three weeks before your desire changed is a better suspect than one you have taken for six years.
The evidence is mostly about men, and that matters
Three of the studies here measured men. Ko's pooled trials drew on male-dominated cardiac and hypertensive populations, Farmakis used erectile function as the declared endpoint, and Silvestri enrolled 96 patients, all male.
One trial did measure both. TOMHS, which ran in the 1990s on a drug list (chlorthalidone, doxazosin, acebutolol) few readers are prescribed today, randomized 902 people with stage I diastolic hypertension, 557 men and 345 women aged 45 to 69, to placebo or one of five active drugs, double-blind, with sexual function assessed by physician interview at baseline and annually. At baseline 14.4% of men and 4.9% of women reported a problem, and through follow-up the rate in women stayed low across every treatment group with no apparent variation by drug type (Grimm et al., 1997). Useful, and limited: a yearly interview is a coarse instrument for female desire, and 2.0% of women reporting difficulty with orgasm at baseline suggests it captured far less than was there.
A 2023 literature review reached the same verdict about the field. Its authors describe sexual dysfunction as showing up mostly as erectile difficulty in men and as reduced desire in women. They add that hypertension itself is associated with both, and that antihypertensive drugs can affect sexual function in ways that reduce adherence (Lou et al., 2023). That paper is a narrative review, so it summarizes published work without pooling data or grading study quality. It maps the territory without measuring it.
This randomized evidence is largely evidence about men. A woman on a beta blocker whose desire has dropped sits outside the population these trials studied. Unmeasured is worse than measured and cleared.
The numbers were fine and I still feel like crap
Blood pressure controlled, labs unremarkable, desire still gone. Hypertension travels with sexual difficulty on its own, before any drug enters the picture. TOMHS shows it at the starting line: 14.4% of men reported a problem at baseline, having just been diagnosed and randomized, and those baseline problems rose with age, with systolic pressure, and with previous antihypertensive drug use. The condition and the vascular aging behind it were already doing work no tablet had done yet.
The TOMHS authors closed with a warning about attribution: similar incidence rates in the placebo group and in most active drug groups, they wrote, caution against routinely blaming antihypertensive medication.
Blame the pill and stop looking, and you stop looking at sleep, alcohol, stress load, weight, thyroid, depression, and every other prescription in the cabinet. We wrote about the frustration of a clean lab panel and a missing sex drive in what to do when your labs come back normal and your libido has not, and the broader picture sits in our guide to low libido in men.
Tired all the time is the bigger signal
In the Ko trials, sexual dysfunction rose 5 per 1000 per year. Fatigue rose 18, more than three times as large, and early-generation beta blockers drove more of it than later ones.
Fatigue is the effect those trials found most clearly, and the one nobody names when they talk about beta blockers and desire. Someone flattened by exhaustion by 9pm has lost something that looks exactly like lost libido from the outside. That mechanism runs through energy and the drug's effect on exercise capacity, which points toward different fixes: dose timing, a switch to a later-generation drug, cardiovascular conditioning. The last one moves in the right direction for blood pressure and for desire at once, which we covered in the research on exercise and libido.
Medications that cause low sex drive: where beta blockers rank
Beta blockers get named first in almost every list of medications that cause low sex drive, and the trial data puts them well down the order.
SSRIs and SNRIs are the clearest example, with rates nowhere near 5 per 1000 per year. We went through what those trials show and what prescribers tend to leave out in antidepressants and low libido. Stimulants prescribed for attention deficit have their own pattern, covered in Adderall and sex drive. The newer GLP-1 drugs are producing reports that run in both directions, tracked in GLP-1 medications and libido. Statins draw the same suspicion, and the randomized record on them is in statins and sex drive.
Anyone on a beta blocker plus an antidepressant who blames the blood pressure tablet has picked the smaller suspect. Bring the whole list to the appointment.
I stopped the meds and it's still gone
Someone comes off the drug, waits, and nothing returns. That happens often, and it is demoralizing. Three explanations fit, and none requires the drug to have done permanent damage.
The first is that the drug was never the cause. If the vascular condition and the years leading up to it were driving the change, removing the tablet leaves the actual driver untouched. TOMHS points that way, given how close the placebo arm ran to the active arms.
The second is expectation, running the other direction. Silvestri's trial shows how strongly belief about a drug shapes what gets reported, and that mechanism does not switch off the day the prescription ends. Two years spent certain your body was broken by a pill builds an expectation that outlives the pill.
The third is that recovery timelines after any medication change are slower than people expect, and the waiting generates anxiety that keeps the problem alive. We wrote about that for a different drug class in libido after stopping antidepressants, and the shape of it transfers. Whatever the cause, go back to the prescriber with the timeline written down: a stopped drug that changed nothing is diagnostic information worth having.
How to work out whether the medication is the cause
You can get most of the way to an answer before your appointment.
- Write the timeline: when the prescription started and when you first noticed the change. Years between the two makes the drug a weak suspect; days makes it a strong one.
- List every medication and supplement you take, over the counter included. Beta blockers are frequently the smallest contributor in a stack of things that each affect desire.
- Separate desire from function. Wanting sex less and responding differently have separate causes, and merging them sends the conversation off course.
- Check what else changed that month. A cardiovascular diagnosis arrives with worry, sleep disruption, dietary changes, and sometimes a new antidepressant.
- Ask what you were told at the start. If a pharmacist or a search result warned you about sexual side effects before your first dose, the Silvestri result applies to you.
The conversation to have with your prescriber
Where NUUD fits, and where it does not
Straight answer, and it points away from most of the people reading this page.
NUUD's own product label carries this caution: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. If you found this article because you take a blood pressure prescription, that caution covers you, and our answer is to talk to your doctor before taking anything of ours. We would sooner lose the sale than write around our own label.
Our supplements are built for people who want more desire and fall outside that caution: no blood pressure prescription, no cardiovascular, renal, or pulmonary condition. For those readers the formula is anchored on the NUUD Mushroom Complex™ with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, and our men's libido support capsules are the standard place to start. They work on desire. No botanical supplement is an answer to a medication side effect, and nothing here should be read as one.
Keep reading
- Antidepressants and low libido, and what doctors leave out
- Libido after stopping antidepressants
- GLP-1 medications and libido
- Adderall and sex drive
Frequently asked questions
Do beta blockers lower sex drive?
Less than their reputation says. A pooled analysis of 15 randomized trials covering more than 35,000 subjects found beta blocker therapy associated with about 5 extra reports of sexual dysfunction per 1000 patients per year (95% CI 2 to 8), one extra report for every 199 people treated for a year. The same analysis found a larger effect on fatigue, at 18 per 1000 per year, and no significant increase in depressive symptoms. Never change a blood pressure prescription on your own.
My sex drive dropped after starting a beta blocker. Is it the pill or is it me?
One trial was built to answer that, and its answer is that information does much of the work. In 96 men newly started on atenolol 50mg daily, reported erectile dysfunction after three months was 3.1% among men blinded to the drug, 15.6% among men told the drug name, and 31.2% among men told the name and its sexual side effects, at P less than 0.01. Placebo reversed the reports about as well as sildenafil. One trial, all male, and none of it means the experience is imaginary: anxiety about a drug produces genuine physical effects.
Does lisinopril or metoprolol cause low sex drive?
Neither has a drug-specific trial result to point to. Metoprolol is a beta blocker, so the pooled beta blocker estimate applies, and it was small. Lisinopril is an ACE inhibitor, and its close relative enalapril produced erection problems at a rate similar to placebo across four years of double-blind follow-up in a 902-patient trial. A network meta-analysis of 25 studies and 7,784 patients found no significant differences between the major antihypertensive classes and no separation from placebo, though its authors rated risk of bias as concerning or high in most included studies.
I stopped the meds and it's still gone. What does that mean?
Most often it means the drug was never the cause. The condition being treated is associated with sexual difficulty on its own, and in a 902-patient randomized trial the placebo group reported erection problems at rates close to most active drug groups, which is why the authors cautioned against routinely blaming the medication. Expectation is the second explanation, since belief about a drug shapes reported symptoms and does not switch off when the prescription ends. Take the timeline back to your prescriber: a stopped drug that changed nothing is useful diagnostic information.
My blood pressure numbers are fine and my sex drive is gone. Is this normal?
It is common, and controlled numbers do not rule out the condition itself as a driver. In the TOMHS trial, 14.4% of men and 4.9% of women reported a sexual problem at baseline, before any study drug was given, and problems in men tracked with age, systolic pressure, and previous antihypertensive use. Fatigue is worth separating out too, since the pooled trial data found a larger effect on it than on sexual function. Sleep, alcohol, mood, and every other prescription in the cabinet belong on the list first.
References
- Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002 Jul 17;288(3):351-7. https://pubmed.ncbi.nlm.nih.gov/12117400/
- Farmakis IT, Pyrgidis N, Doundoulakis I, et al. Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis. Cardiovascular Drugs and Therapy. 2022 Oct;36(5):903-914. https://pubmed.ncbi.nlm.nih.gov/33945044/
- Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. European Heart Journal. 2003 Nov;24(21):1928-32. https://pubmed.ncbi.nlm.nih.gov/14585251/
- Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997 Jan;29(1 Pt 1):8-14. https://pubmed.ncbi.nlm.nih.gov/9039073/
- Lou IX, Chen J, Ali K, Chen Q. Relationship Between Hypertension, Antihypertensive Drugs and Sexual Dysfunction in Men and Women: A Literature Review. Vascular Health and Risk Management. 2023 Nov 3;19:691-705. https://pubmed.ncbi.nlm.nih.gov/37941540/
This article is for general education and is not medical advice. Never stop, reduce, or change a blood pressure medication without talking to the clinician who prescribed it. NUUD is a botanical supplement. These statements have not been evaluated by the FDA, and the product is not intended to diagnose, treat, prevent, or cure any disease. NUUD's label advises avoiding use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or are sensitive to any of the ingredients.
